Regorafenib
- Generic Name
- Regorafenib
- Brand Names
- Stivarga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H15ClF4N4O3
- CAS Number
- 755037-03-7
- Unique Ingredient Identifier
- 24T2A1DOYB
- Background
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
- Indication
Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumour (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. Regorafenib is also indicated for the treatment of patients with hepatocellular carcinoma (HCC) previously treated with sorafenib.
- Associated Conditions
- Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Gastrointestinal Stromal Tumor (GIST), Locally advanced Gastrointestinal stromal tumor, Unresectable Gastrointestinal stromal tumor
Regorafenib Alone or in Combination With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
- Conditions
- Microsatellite Stable Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 90
- Registration Number
- NCT05963490
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Adenocarcinoma
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 103
- Registration Number
- NCT05942768
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
- Conditions
- Colorectal CancerColon CancerRectum Cancer
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05900648
The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases
- Conditions
- Colorectal Liver Metastases
- Interventions
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 20
- Registration Number
- NCT05877001
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions
- Conditions
- Metastatic Colorectal Cancer (mCRC)
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 818
- Registration Number
- NCT05839951
- Locations
- 🇺🇸
Many locations, Whippany, New Jersey, United States
Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 24
- Registration Number
- NCT05830084
- Locations
- 🇦🇺
Perth Children's Hospital, Perth, Australia
🇩🇰Rigshospitalet, Copenhagen, Denmark
🇮🇹Istituto Nazionale dei Tumori, Milan, Italy
Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Wei Zhang
- Target Recruit Count
- 30
- Registration Number
- NCT05818267
- Locations
- 🇨🇳
Department of Colorectal Surgery in Changhai Hospital, Shanghai, Shanghai, China
Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy
- Conditions
- Hepatocellular CarcinomaTranscatheter Arterial ChEmoembolizationRegorafenib
- Interventions
- Procedure: TACE
- First Posted Date
- 2023-04-13
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- WenBo Guo
- Target Recruit Count
- 192
- Registration Number
- NCT05811481
- Locations
- 🇨🇳
FirstSunYetSen, Guangzhou, Guangdong, China
Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases
- Conditions
- Colorectal Cancer Liver MetastasesRegorafenib
- Interventions
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 126
- Registration Number
- NCT05794971
- Locations
- 🇨🇳
Bo Zhang, Guangdong, Guangzhou, China
Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2025-03-11
- Target Recruit Count
- 7
- Registration Number
- NCT05770882
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.